AstraZeneca Canadian investment to drive R&D growth
By Catherine Eckford (European Pharmaceutical Review)
M&A outlook for pharma in 2025
By Catherine Eckford (European Pharmaceutical Review)
FDA approves innovative monotherapy for treatment-resistant depression
By Catherine Eckford (European Pharmaceutical Review)
Early-phase ATMP clinical trials see promising growth
By Catherine Eckford (European Pharmaceutical Review)
Hydrogel encapsulation: unlocking the potential of cell therapies for targeted…
By Francis Karanu (Likarda), Stephen Harrington (Likarda)
The year ahead for RNA therapeutic development and manufacturing
By Dr Kate Broderick (Maravai Life Sciences and TriLink Biotechnologies)